Tranexamic%2525252525252520acid

# Tranexamic Acid ## Overview Tranexamic acid (TXA) is a synthetic lysine analog that acts as a potent antifibrinolytic agent. It competitively inhibits the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots and stabilizing hemostasis. ## Primary Indications * Treatment or prevention of excessive bleeding in trauma (CRASH-2 protocol). * Postpartum hemorrhage (WOMAN trial protocol). * Heavy menstrual bleeding. * Prophylaxis in surgical procedures (cardiac, orthopedic, dental). * Hereditary angioedema (off-label). ## Adult Dosing * **Trauma/Acute Hemorrhage:** 1 g IV loading dose over 10 minutes, followed by 1 g IV infusion over 8 hours (or 1 g IV every 8 hours depending on institutional protocol). * **Heavy Menstrual Bleeding:** 1.3 g orally three times daily for up to 5 days during menstruation. * **Surgical Prophylaxis:** Varies widely by specialty; often 10–20 mg/kg IV bolus prior to incision. ## Pediatric Dosing * **Trauma/Hemorrhage:** 10–15 mg/kg IV bolus (max 1 g), followed by 2–5 mg/kg/hour infusion, or 10 mg/kg IV every 8 hours. * *Note:* Protocols vary significantly; consultation with pediatric hematology or institutional formularies is mandatory. ## Dose Adjustments * **Renal Impairment:** Requires dose reduction in patients with CrCl < 50 mL/min. * CrCl 30–50 mL/min: 10 mg/kg IV daily or 5 mg/kg q12h. * CrCl < 30 mL/min: 5–10 mg/kg IV every 24–48 hours. * **Hepatic Impairment:** No formal adjustment required, but use caution. ## Contraindications * Active intravascular clotting (thromboembolic disease). * History of deep vein thrombosis (DVT) or pulmonary embolism (PE). * Acquired defective color vision (prevents monitoring of retinal changes). * Subarachnoid hemorrhage (risk of cerebral ischemia/seizures). ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain. * **Serious:** Thromboembolic events (MI, DVT, PE, stroke), seizures (particularly with rapid IV injection or high doses), visual disturbances, and allergic skin reactions. ## Key Drug Interactions * **Hormonal Contraceptives:** Concomitant use with estrogen-containing contraceptives may increase the risk of thrombosis. * **Thrombolytics/Procoagulants:** Risk of antagonistic effect; avoid combination with Factor IX complex concentrates or anti-inhibitor coagulant complexes due to potential risk of thrombosis. ## Monitoring * Monitor for signs of thromboembolism (e.g., leg swelling, chest pain, dyspnea). * Neurological status (seizure risk is higher in cardiac surgery/high-dose settings). * Renal function (BUN/Cr) to adjust dosing as necessary. * Ophthalmologic exams if treatment exceeds 7 days (rarely required for acute bleeding). ## Clinical Pearls * **Seizure Risk:** Rapid IV injection can trigger seizures. Always administer as a slow infusion or slow bolus. * **Timing:** Efficacy is time-dependent; the "golden hour" for trauma administration is critical. Benefits decrease significantly if administered >3 hours post-injury. * **Off-label use:** Frequently used for epistaxis or trauma-related hemorrhages, but always check local clinical pathways. *** **Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing, contraindications, and clinical protocols vary by institution and patient-specific needs. Always verify current prescribing information, drug monographs, and local hospital protocols before administration.